Crosstalk between Tumor-Associated Macrophages and MicroRNAs: A Key Role in Tumor Microenvironment

Zhou, Xianghong; Chen, Bin; Zhang, Zilong; Huang, Yin; Li, Jinze; Wang, Qiang; Cao, Dehong; Ai, Jianzhong

doi:10.3390/ijms232113258

Cited by 6 publications

(7 citation statements)

References 168 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prior investigations have established that miRNAs play a pivotal role in modulating the polarization of TAMs 60 . This revelation opens up a new avenue for leveraging miRNAs as a novel approach to tumour immunotherapy.…”

Section: Engineered Exosomes For Immunomodulation In Bcmentioning

confidence: 95%

“…Prior investigations have established that miRNAs play a pivotal role in modulating the polarization of TAMs. 60 This revelation opens up a new avenue for leveraging miRNAs as a novel approach to tumour immunotherapy. Furthermore, exosomes, as emerging carriers of miRNAs, offer a promising means to actively engage in the immune regulation of tumours.…”

Section: Engineered Exosomes For Immunomodulation In Bcmentioning

confidence: 99%

See 1 more Smart Citation

Engineering exosomes to reshape the immune microenvironment in breast cancer: Molecular insights and therapeutic opportunities

Cao,

Lv,

Wei

2024

Clinical & Translational Med

View full text Add to dashboard Cite

BackgroundBreast cancer remains a global health challenge, necessitating innovative therapeutic approaches. Immunomodulation and immunotherapy have emerged as promising strategies for breast cancer treatment. Engineered exosomes are the sort of exosomes modified with surface decoration and internal therapeutic molecules. Through suitable modifications, engineered exosomes exhibit the capability to overcome the limitations associated with traditional therapeutic approaches. This ability opens up novel avenues for the development of more effective, personalized, and minimally invasive interventions.Main bodyIn this comprehensive review, we explore the molecular insights and therapeutic potential of engineered exosomes in breast cancer. We discuss the strategies employed for exosome engineering and delve into their molecular mechanisms in reshaping the immune microenvironment of breast cancer.ConclusionsBy elucidating the contribution of engineered exosomes to breast cancer immunomodulation, this review underscores the transformative potential of this emerging field for improving breast cancer therapy.Highlights Surface modification of exosomes can improve the targeting specificity. The engineered exosome‐loaded immunomodulatory cargo regulates the tumour immune microenvironment. Engineered exosomes are involved in the immune regulation of breast cancer.

show abstract

Section: Engineered Exosomes For Immunomodulation In Bcmentioning

confidence: 95%

Section: Engineered Exosomes For Immunomodulation In Bcmentioning

confidence: 99%

Engineering exosomes to reshape the immune microenvironment in breast cancer: Molecular insights and therapeutic opportunities

Cao,

Lv,

Wei

2024

Clinical & Translational Med

View full text Add to dashboard Cite

show abstract

“…M2 macrophage-derived exosomal microRNA-155-5p was found to be associated with increased IL-6 expression. This microRNA promotes immune escape and cancer cell metastasis [ 67 ].…”

Section: M2-like Macrophagesmentioning

confidence: 99%

Tumor-Associated Macrophage Subsets: Shaping Polarization and Targeting

Zhang

Sioud

2023

IJMS

View full text Add to dashboard Cite

The tumor microenvironment (TME) is a critical regulator of tumor growth, progression, and metastasis. Among the innate immune cells recruited to the tumor site, macrophages are the most abundant cell population and are present at all stages of tumor progression. They undergo M1/M2 polarization in response to signals derived from TME. M1 macrophages suppress tumor growth, while their M2 counterparts exert pro-tumoral effects by promoting tumor growth, angiogenesis, metastasis, and resistance to current therapies. Several subsets of the M2 phenotype have been observed, often denoted as M2a, M2b, M2c, and M2d. These are induced by different stimuli and differ in phenotypes as well as functions. In this review, we discuss the key features of each M2 subset, their implications in cancers, and highlight the strategies that are being developed to harness TAMs for cancer treatment.

show abstract

“…Strategies for macrophage cell therapy are based on the fact that monocytes are capable to act as Trojan horses, delivering small molecules such as cytokines, miRNA [ 156 , 157 ], or nanoparticles to the TME [ 158 , 159 ], and it is also possible to modify these cells with engineered receptors to achieve a better homing performance into tumors [ 160 ]. In concordance, cell delivery with other cells such as mesenchymal stem cells, monocytes, and neutrophils has been also used in the targeted delivery of a wide variety of anticancer agents, including nanoparticles, chemotherapeutics, proteins, suicide genes, and viruses [ 161 , 162 , 163 , 164 ].…”

Section: Therapeutic Strategies Focused On Tams Of Gbmmentioning

confidence: 99%

Exploring Monocytes-Macrophages in Immune Microenvironment of Glioblastoma for the Design of Novel Therapeutic Strategies

et al. 2023

View full text Add to dashboard Cite

Gliomas are primary malignant brain tumors. These tumors seem to be more and more frequent, not only because of a true increase in their incidence, but also due to the increase in life expectancy of the general population. Among gliomas, malignant gliomas and more specifically glioblastomas (GBM) are a challenge in their diagnosis and treatment. There are few effective therapies for these tumors, and patients with GBM fare poorly, even after aggressive surgery, chemotherapy, and radiation. Over the last decade, it is now appreciated that these tumors are composed of numerous distinct tumoral and non-tumoral cell populations, which could each influence the overall tumor biology and response to therapies. Monocytes have been proved to actively participate in tumor growth, giving rise to the support of tumor-associated macrophages (TAMs). In GBM, TAMs represent up to one half of the tumor mass cells, including both infiltrating macrophages and resident brain microglia. Infiltrating macrophages/monocytes constituted ~ 85% of the total TAM population, they have immune functions, and they can release a wide array of growth factors and cytokines in response to those factors produced by tumor and non-tumor cells from the tumor microenvironment (TME). A brief review of the literature shows that this cell population has been increasingly studied in GBM TME to understand its role in tumor progression and therapeutic resistance. Through the knowledge of its biology and protumoral function, the development of therapeutic strategies that employ their recruitment as well as the modulation of their immunological phenotype, and even the eradication of the cell population, can be harnessed for therapeutic benefit. This revision aims to summarize GBM TME and localization in tumor niches with special focus on TAM population, its origin and functions in tumor progression and resistance to conventional and experimental GBM treatments. Moreover, recent advances on the development of TAM cell targeting and new cellular therapeutic strategies based on monocyte/macrophages recruitment to eradicate GBM are discussed as complementary therapeutics.

show abstract

Crosstalk between Tumor-Associated Macrophages and MicroRNAs: A Key Role in Tumor Microenvironment

Cited by 6 publications

References 168 publications

Engineering exosomes to reshape the immune microenvironment in breast cancer: Molecular insights and therapeutic opportunities

Engineering exosomes to reshape the immune microenvironment in breast cancer: Molecular insights and therapeutic opportunities

Tumor-Associated Macrophage Subsets: Shaping Polarization and Targeting

Exploring Monocytes-Macrophages in Immune Microenvironment of Glioblastoma for the Design of Novel Therapeutic Strategies

Contact Info

Product

Resources

About